Peptide

CJC-1295

Synthetic GHRH analog with a prolonged half-life (28 days) thanks to albumin binding; raises GH and IGF-1 in a sustained way. Phase 2 trial halted after a death (unrelated).

Regulatory status

Not approved

FDA (U.S.): Not approved; its clinical development was abandoned after phase 2. The FDA noted possible immunogenicity and reported serious adverse effects (increased heart rate, systemic vasodilatory reaction) when evaluating it for compounding (proposal withdrawn).

EMA (EU): Not approved.

How to take it

Investigated regimen: 1-2 mg subcutaneously weekly. Not FDA-approved. Banned by WADA.

Safety

Data limited to phase 1/2. Phase 2 trial halted after a death (inconclusive regarding causality). Raises IGF-1 persistently: caution with a history of cancer.

Effect by goal · level of evidence

Growth hormone and IGF-1

improves Moderate phase 1/2 (A)

↑ GH 2-10× · ↑ IGF-1 1.5-3×

Raises GH 2× to 10× and IGF-1 1.5× to 3× for up to 28 days in phase 1/2.

See the study (phase 1/2) →

Growth hormone and IGF-1

improves (modest) Low clinical trial (A)

Limited data

In healthy adults, one injection of CJC-1295 raised growth hormone and IGF-1 for days in a dose-dependent way. There are no human studies showing more lean mass.

View the study (clinical trial) →

Information, not medical advice. Scientific evidence reflects the quality of the studies.